In addition, a detailed examination of the participants’ immune response not only showed the systemic reaction, but also the response to remote mucus membranes. In the blood, two types of antibodies (IGA and IGG) increased several times after vaccination compared to the Placebo Group. The biggest reaction group was the one who received high dose.
A test that acts as a surrogate to make the antibody’s response to the Noro virus indicates that antibodies produced by the vaccine can prevent the virus. Additional tests have shown that cellular immune responses have also been activated and that the systemic reaction resulted in the protection of intestinal away places – namely mouth and nose. The secret IGA against the Noro virus jumped a significant jump for wholesale tests and nose shrubs.
In the first two months after vaccination, the immune response was the strongest and decreased over time, but some remained intact for about seven months. When scientists see the differences between two ages groups (55-65 and 65-80), they did not see important differences, suggesting that this vaccine is equally effective in the old group.
Overall, Waxart scientists concluded that the vaccine was “capable of preventing infection, viral shading and transmission.”
He wrote, “Overall, the VXA-G1.1-NN administration has detected strong and sustainable immunogies in both places of the VXA-G1.1-NN administration, which is a fascinating result that low cellular and mucus exception is common in the older population.”
Not so good news
The approach is not completely pink, though – some bad news. Although the immune response has increased in important steps in terms of data during this small phase trial, it is unclear if it is akin to real -life protection. And there is some good reason to be careful. In 2023, Waxart The results issued by the Challenge StudyIn which 141 brave spirits (76 vaccinated and 65 placebo) were deliberately exposed to the Nuro virus to find out if the vaccine was protective or not. The results were weak: 53 members of the Placebo group (81.5 %) were infected with the Noro virus, as was determined by the PCR test in search of genetic evidence of the virus in their stools-and 76 vaccinated individuals (60 %). He only worked on a vaccine offer 29 % lower relative risk of infection. Given whether the victims caused severe gastrointestinal symptoms, the vaccine was about 21 %: 34 vaccine people (48 %) vs. 37 Placebo Group members (57 %) developed symptoms.